Last mentioned: 15h ago
Financial Reporting
Lifeward scheduled to report Q4 and full-year 2025 financial results.
Shareholder Approval
Lifeward shareholders vote in favor of the strategic partnership with Oramed.
Nasdaq Compliance
Lifeward regains compliance with Nasdaq minimum bid price requirements.
Hologic, Inc. (NASDAQ: HOLX) has experienced a dramatic 71.7% increase in short interest, signaling a significant shift in investor sentiment toward the medical technology leader. This surge suggests growing skepticism regarding the company's near-term growth prospects in its core women's health and diagnostics segments.
Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.